Does the media prefer CPRX or JBIO?

In the previous week, Jade Biosciences had 2 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Jade Biosciences and 2 mentions for Catalyst Pharmaceuticals. Jade Biosciences' average media sentiment score of 1.16 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JBIO or RCUS?

In the previous week, Jade Biosciences had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 4 mentions for Jade Biosciences and 3 mentions for Arcus Biosciences. Jade Biosciences' average media sentiment score of 1.16 beat Arcus Biosciences' score of 0.52 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JBIO or DNLI more profitable?

Jade Biosciences' return on equity of -51.34% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -51.34% -47.32% Denali Therapeutics N/A -52.20% -43.86%

Does the media favor JBIO or DNLI?

In the previous week, Denali Therapeutics had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 5 mentions for Denali Therapeutics and 4 mentions for Jade Biosciences. Denali Therapeutics' average media sentiment score of 1.20 beat Jade Biosciences' score of 1.16 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or JBIO more profitable?

Relay Therapeutics' return on equity of -43.94% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Jade Biosciences N/A -51.34% -47.32%

Does the media refer more to RLAY or JBIO?

In the previous week, Relay Therapeutics had 9 more articles in the media than Jade Biosciences. MarketBeat recorded 13 mentions for Relay Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.16 beat Relay Therapeutics' score of 0.84 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, GPCR or JBIO?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Jade Biosciences N/A N/A -$127.41M -$2.02 N/A

Is GPCR or JBIO more profitable?

Structure Therapeutics' return on equity of -24.91% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Jade Biosciences N/A -51.34% -47.32%

Does the media refer more to GPCR or JBIO?

In the previous week, Structure Therapeutics had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Structure Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.16 beat Structure Therapeutics' score of 1.15 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jade Biosciences (JBIO) Competitors

$21.07 +1.92 (+10.02%)

As of 10:07 AM Eastern

Compare

JBIO vs. CPRX, RCUS, DNLI, RLAY, and GPCR

Should you buy Jade Biosciences stock or one of its competitors? MarketBeat compares Jade Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jade Biosciences include Catalyst Pharmaceuticals (CPRX), Arcus Biosciences (RCUS), Denali Therapeutics (DNLI), Relay Therapeutics (RLAY), and Structure Therapeutics (GPCR).

How does Jade Biosciences compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Jade Biosciences' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Jade Biosciences	N/A	-51.34%	-47.32%

Catalyst Pharmaceuticals currently has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Jade Biosciences has a consensus target price of $51.57, suggesting a potential upside of 147.61%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Jade Biosciences had 2 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Jade Biosciences and 2 mentions for Catalyst Pharmaceuticals. Jade Biosciences' average media sentiment score of 1.16 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Summary

Catalyst Pharmaceuticals beats Jade Biosciences on 8 of the 15 factors compared between the two stocks.

How does Jade Biosciences compare to Arcus Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Jade Biosciences has higher earnings, but lower revenue than Arcus Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Arcus Biosciences	$247M	14.54	-$353M	-$3.18	N/A

Jade Biosciences has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Jade Biosciences' return on equity of -51.34% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

92.9% of Arcus Biosciences shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Jade Biosciences has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

In the previous week, Jade Biosciences had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 4 mentions for Jade Biosciences and 3 mentions for Arcus Biosciences. Jade Biosciences' average media sentiment score of 1.16 beat Arcus Biosciences' score of 0.52 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences currently has a consensus price target of $51.57, suggesting a potential upside of 147.61%. Arcus Biosciences has a consensus price target of $36.40, suggesting a potential upside of 27.48%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Jade Biosciences is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Jade Biosciences beats Arcus Biosciences on 11 of the 16 factors compared between the two stocks.

How does Jade Biosciences compare to Denali Therapeutics?

Jade Biosciences (NASDAQ:JBIO) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Jade Biosciences has higher earnings, but lower revenue than Denali Therapeutics. Jade Biosciences is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Denali Therapeutics	$330.53M	11.39	-$512.54M	-$2.88	N/A

Jade Biosciences' return on equity of -51.34% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Denali Therapeutics	N/A	-52.20%	-43.86%

Jade Biosciences has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

In the previous week, Denali Therapeutics had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 5 mentions for Denali Therapeutics and 4 mentions for Jade Biosciences. Denali Therapeutics' average media sentiment score of 1.20 beat Jade Biosciences' score of 1.16 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences presently has a consensus target price of $51.57, suggesting a potential upside of 147.61%. Denali Therapeutics has a consensus target price of $35.17, suggesting a potential upside of 48.19%. Given Jade Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Jade Biosciences is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

92.9% of Denali Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Jade Biosciences beats Denali Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Jade Biosciences compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Relay Therapeutics presently has a consensus target price of $24.92, suggesting a potential upside of 28.91%. Jade Biosciences has a consensus target price of $51.57, suggesting a potential upside of 147.61%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Jade Biosciences has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	241.25	-$276.48M	-$1.57	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Relay Therapeutics' return on equity of -43.94% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Jade Biosciences	N/A	-51.34%	-47.32%

In the previous week, Relay Therapeutics had 9 more articles in the media than Jade Biosciences. MarketBeat recorded 13 mentions for Relay Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.16 beat Relay Therapeutics' score of 0.84 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 23.1% of Jade Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Relay Therapeutics beats Jade Biosciences on 8 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

In the previous week, Structure Therapeutics had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Structure Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.16 beat Structure Therapeutics' score of 1.15 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics' return on equity of -24.91% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Jade Biosciences	N/A	-51.34%	-47.32%

Structure Therapeutics currently has a consensus price target of $110.55, suggesting a potential upside of 124.08%. Jade Biosciences has a consensus price target of $51.57, suggesting a potential upside of 147.61%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Jade Biosciences is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Structure Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Structure Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

91.8% of Structure Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Structure Therapeutics and Jade Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Jade Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JBIO vs. The Competition

Export

Metric	Jade Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$997.32M	$3.55B	$6.86B	$12.43B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-10.00	7.29	280.73	24.99
Price / Sales	N/A	1,266.92	643.21	112.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	3.09	16.69	10.94	6.21
Net Income	-$127.41M	-$12.54M	$3.48B	$347.49M
7 Day Performance	5.73%	0.24%	0.78%	1.28%
1 Month Performance	-3.17%	-7.52%	-4.20%	-3.62%
1 Year Performance	185.71%	47.22%	61.51%	18.37%

Jade Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JBIO Jade Biosciences	3.2727 of 5 stars	$20.83 +8.8%	$51.57 +147.6%	+177.9%	$997.32M	N/A	N/A	20	News Coverage Positive News
CPRX Catalyst Pharmaceuticals	3.411 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	Upcoming Earnings
RCUS Arcus Biosciences	2.6882 of 5 stars	$29.71 -0.9%	$36.40 +22.5%	+202.4%	$3.74B	$247M	N/A	500	Upcoming Earnings
DNLI Denali Therapeutics	2.8935 of 5 stars	$23.46 -0.8%	$35.17 +49.9%	+72.2%	$3.72B	$330.53M	N/A	430	Upcoming Earnings Gap Up
RLAY Relay Therapeutics	3.2304 of 5 stars	$19.09 -0.9%	$24.92 +30.5%	+458.9%	$3.66B	$15.35M	N/A	330	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JBIO) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jade Biosciences (JBIO) Competitors

JBIO vs. CPRX, RCUS, DNLI, RLAY, and GPCR

How does Jade Biosciences compare to Catalyst Pharmaceuticals?

Summary

How does Jade Biosciences compare to Arcus Biosciences?

Summary

How does Jade Biosciences compare to Denali Therapeutics?

Summary

How does Jade Biosciences compare to Relay Therapeutics?

Summary

How does Jade Biosciences compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jade Biosciences (JBIO) Competitors

JBIO vs. CPRX, RCUS, DNLI, RLAY, and GPCR

How does Jade Biosciences compare to Catalyst Pharmaceuticals?

Do insiders and institutionals hold more shares of CPRX or JBIO?

Is CPRX or JBIO more profitable?

Do analysts rate CPRX or JBIO?

Does the media prefer CPRX or JBIO?

Which has more risk and volatility, CPRX or JBIO?

Which has preferable valuation & earnings, CPRX or JBIO?

Summary

How does Jade Biosciences compare to Arcus Biosciences?

Which has preferable valuation & earnings, JBIO or RCUS?

Is JBIO or RCUS more profitable?

Do insiders & institutionals have more ownership in JBIO or RCUS?

Which has more risk & volatility, JBIO or RCUS?

Does the media refer more to JBIO or RCUS?

Do analysts prefer JBIO or RCUS?

Summary

How does Jade Biosciences compare to Denali Therapeutics?

Which has preferable valuation and earnings, JBIO or DNLI?

Is JBIO or DNLI more profitable?

Which has more volatility and risk, JBIO or DNLI?

Does the media favor JBIO or DNLI?

Do analysts rate JBIO or DNLI?

Do institutionals & insiders hold more shares of JBIO or DNLI?

Summary

How does Jade Biosciences compare to Relay Therapeutics?

Do analysts rate RLAY or JBIO?

Which has more risk and volatility, RLAY or JBIO?

Which has better earnings and valuation, RLAY or JBIO?

Is RLAY or JBIO more profitable?

Does the media refer more to RLAY or JBIO?

Do insiders and institutionals hold more shares of RLAY or JBIO?

Summary

How does Jade Biosciences compare to Structure Therapeutics?

Does the media refer more to GPCR or JBIO?

Is GPCR or JBIO more profitable?

Do analysts recommend GPCR or JBIO?

Which has higher valuation and earnings, GPCR or JBIO?

Which has more volatility and risk, GPCR or JBIO?

Do insiders & institutionals hold more shares of GPCR or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools